On Monday, May 22, the next meeting of the Transparency Council.
The agenda includes:
Preparation of positions on drug evaluation:
- Adtralza (tralokinumabum) under drug program B.124 "Treatment of patients with severe forms of atopic dermatitis (I...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
